Patent · US Expired

84P2A9: a prostate and testis specific protein highly expressed in prostate cancer

US7510855B2 · kind B2 · utility

0Cited by
0References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 26, 2001
Grant dateMar 31, 2009
Priority date
Expiry dateApr 7, 2023

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A novel gene (designated 84P2A9) and its encoded protein is described. While 84P2A9 exhibits prostate and testis specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, testis, kidney, brain, bone, skin, ovarian, breast, pancreas, colon, lymphocytic and lung cancers. Consequently, 84P2A9 provides a diagnostic and/or therapeutic target for cancers, and the 84P2A9 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.